BIO vs GKOS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BIO · Bio-Rad Laboratories$358.90 ▼ 2.34%
GKOS · Glaukos$237.31 ▼ 0.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BIO +11.3%
- GKOS +142.0%
Head to head
| Metric | BIO | GKOS |
|---|---|---|
| Price | $358.90 | $237.31 |
| Change today | ▼ 2.34% | ▼ 0.33% |
| Market cap | $9.65B | $14.05B |
| Return, 3 months | -6.0% | +27.8% |
| Return, year to date | +18.5% | +110.2% |
| Return, 1 year | +13.3% | +138.2% |
| P/E (TTM) | 9.5 | – |
| P/B | 1.3 | 19.6 |
| P/E percentile vs own 5y | 81st | 1st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +0.5% | +58.0% |
| Net profit growth (YoY) | +234.1% | +112.4% |
| Gross margin | 51.3% | 64.8% |
| Operating margin | 6.2% | -25.3% |
| Net margin | 39.5% | -24.6% |
| Return on equity | 14.3% | -22.8% |
| Analyst target vs. price | +22.6% | +0.2% |
| Analyst buy share | 100% | 91% |
| RSI (14) | 43 | 61 |
| 30-day volatility | 30.3% | 97.4% |
| Max drawdown, 1 year | -27.2% | -28.4% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GKOS is the largest of the group by market value.
- GKOS has returned the most over the past year.
- GKOS is growing revenue fastest.
- BIO keeps the most profit per dollar of sales.
- BIO has been the calmest stock over the last 30 days.